DRESSING TO TREAT A FABRIC PLACE WITH NEGATIVE PRESSURE, APPLIANCE TO TREAT A FABRIC PLACE WITH NEGA

专利摘要:
It is a dressing that can comprise a collector that has a first flat surface and a second flat surface opposite the first flat surface, and a first layer adjacent to the first flat surface and a second layer adjacent to the second flat surface. The first layer and the second layer can be laminated to the first flat surface and the second flat surface, respectively. Pressure-responsive fluid restrictions through at least one of the first layer and the second layer can be adjacent to the collector. The first layer and the second layer can also form a sleeve or an envelope around the collector in some embodiments. At least one of the first layer and the second layer can be configured to be arranged between the collector and a fabric location in use. In some instances, the dressing may have a smooth or matte surface configured to contact a tissue site.
公开号:BR112019025760A2
申请号:R112019025760-8
申请日:2018-06-05
公开日:2020-06-23
发明作者:Brian Locke Christopher；Christopher Brian Locke；Mark Robinson Timothy；Timothy Mark Robinson
申请人:Kci Licensing, Inc.；
IPC主号:

专利说明:

[001] [001] This application claims the benefit, under 35 U.S.C. § 119 (e), of the filing of the U.S. Provisional Patent Application under serial number 62 / 516,540, entitled “TISSUE CONTACT INTERFACE”, filed on June 7, 2017; U.S. Provisional Patent Application under serial number 62 / 516,550, entitled “COMPOSITE DRESSINGS FOR IMPROVED GRANULATION AND REDUCED MACERATION WITH NEGATIVE-PRESSURE TREATMENT” filed June 7, 2017; and U.S. Provisional Patent Application under serial number 62 / 516,566, entitled “COMPOSITE
[002] [002] The invention presented in the appended claims relates, in general, to tissue treatment systems and, more particularly, but without limitation, to dressings for tissue treatment and methods of using dressings for tissue treatment. BACKGROUND
[003] [003] Clinical studies and practice have shown that reducing pressure in proximity to a tissue site can increase and accelerate new tissue growth at the tissue site. The applications of this phenomenon are numerous, but it has proved to be particularly advantageous for treating injuries. Regardless of the etiology of an injury, be it trauma, surgery, or another cause, proper care of the wound is important to the outcome. The treatment of wounds or other tissue with reduced pressure can also be called "negative pressure therapy", but it is also known by other names, including "negative pressure injury therapy", "negative pressure therapy", "therapy vacuum "," vacuum assisted closing "and" topical negative pressure ", for example. Negative pressure therapy can provide a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow and microdeformation of tissue at an injury site. Together, these benefits can increase the development of granulation tissue and reduce healing times.
[004] [004] There is also wide acceptance that cleaning a tissue site can be highly beneficial for new tissue growth. For example, a wound can be washed with a flow of liquid solution, or a cavity can be washed with the use of a liquid solution for therapeutic purposes. These practices are commonly called "irrigation" and "washing" respectively. "Instillation" is another practice that generally refers to a process of slowly introducing fluid into a tissue site and leaving the fluid for a prescribed period of time before removing the fluid. For example, the instillation of topical treatment solutions into a wound bed can be combined with negative pressure therapy to further promote wound healing by loss of soluble contaminants in a wound bed and removal of infectious material. As a result, the soluble bacterial extent can be decreased, contaminants removed and the wound cleaned.
[005] [005] While the clinical benefits of negative pressure therapy and / or instillation therapy are widely known, improvements to therapy systems, components and processes can benefit healthcare professionals and patients. BRIEF SUMMARY
[006] [006] New and useful systems, devices and methods for treating tissue in a negative pressure therapy environment are presented in the appended claims. Illustrative modalities are also provided to enable an element skilled in the art to make or use the claimed subject.
[007] [007] For example, in some embodiments, a dressing for tissue treatment may be a composite of dressing layers, including a removable film, a perforated polymer film, an open cell foam and an adhesive surgical field. Some dressings may also include a bonded silicone that has perforations. The perforation pattern of the polymeric film can be aligned with the perforation pattern of at least one central area of the silicone. In some embodiments, the perforations may be grooves or slits. In some instances, the open cell foam may be a cross-linked foam, and may be relatively thin and hydrophobic to reduce the fluid's holding capacity of the dressing. The foam can also be thin to reduce the dressing profile and increase flexibility, which can enable it to conform to wound beds and other tissue sites under negative pressure.
[008] [008] More generally, some modalities of a dressing can comprise a collector that has a first surface and a second surface opposite the first surface, and a first layer adjacent to the first surface and a second layer adjacent to the second surface. In some examples, the first layer and the second layer can be laminated to the first surface and the second surface respectively. Fluid restrictions through at least one of the first layer and the second layer can be adjacent to the collector. The first layer and the second layer can also form a sleeve or an envelope around the collector in some embodiments. At least one of the first layer and the second layer can be configured to be arranged between the collector and a fabric location in use. In some instances, the dressing may have a smooth or matte surface configured to contact a tissue site.
[009] [009] In some examples, the first layer and the second layer may each comprise or consist essentially of a polymeric film. In more specific examples, the polymeric film may be hydrophobic, and may have a contact angle with water greater than 90 degrees. Examples of polymeric films may include, without limitation, polyethylene, polyurethane, acrylics, polyolefins, polyacetates, polyamides, polyesters, polyether block amide, thermoplastic vulcanized, polyethers and polyvinyl alcohol.
[0010] [0010] In some embodiments, fluid restrictions may comprise or consist essentially of elastic passages in the polymeric film. In the additional embodiments, the elastic passages are normally closed, for example, closed in the absence of a pressure gradient. For example, elastic passages are responsive to a pressure gradient. For example, fluid constraints may comprise or consist essentially of fenestrations, grooves or cracks in the film that open or expand in response to a pressure gradient.
[0011] [0011] In some embodiments, the collector may comprise a foam, and, in more particular examples, it may comprise or consist essentially of a cross-linked polymeric foam. A hydrophobic collector that has a thickness of less than 7 millimeters and a free volume of at least 90% can be suitable for many therapeutic applications.
[0012] [0012] In some embodiments, a dressing may comprise a collector formed from a hydrophobic material, a film that substantially involves the collector and a plurality of fluid passages through the film. The film can be formed from a hydrophobic material, and the plurality of fluid passages can be configured to expand in response to a pressure gradient across the film.
[0013] [0013] Some modalities of a dressing may comprise a first layer of film, wherein a second layer comprises a collector adjacent to the first layer, a third layer of the film adjacent to the collector opposite the first layer, and a plurality of fluid restrictions across of the film of at least one of the first layer and the third layer. The first and third layer films can each have a flat surface texture, and the plurality of fluid constraints can be configured to be responsive to a pressure gradient through fluid constraints.
[0014] [0014] An apparatus for treating a tissue site with negative pressure is also described in this document, in which some exemplary embodiments include a tissue interface comprising a collector and a film covering at least two sides of the collector, the collector and the film formed from a hydrophobic material; a plurality of elastomeric valves across the film, the plurality of elastomeric valves configured to expand in response to a pressure gradient across the film; and a cover configured to be attached to the fabric location. The cover and fabric interface can be mounted in a stacked relationship with the cover configured to be attached to a fixation surface adjacent to the fabric location. The fabric interface can additionally comprise a sealing layer in some embodiments, which can be arranged adjacent to the film and configured to contact the fabric location. At least one opening in the sealing layer can be fluidly coupled to at least one of the elastomeric valves in the film. Some embodiments of the apparatus may additionally include a source of negative pressure fluidly coupled to the tissue interface.
[0015] [0015] In other examples, a method of promoting granulation in a superficial wound may comprise applying a dressing to the superficial wound, wherein the dressing comprises a cover, a collector that has a first flat surface and a second flat surface opposite the first flat surface, and a perforated polymer film covering at least the first flat surface and the second flat surface. The perforated polymeric film can be sealed in the superficial wound and cover at least a portion of a periphery adjacent to the superficial wound. The cover can be attached to the epidermis around the perforated polymer film. The dressing can be fluidly attached to a negative pressure source, and the negative pressure from the negative pressure source can be applied to the dressing.
[0016] [0016] Advantages of the claimed subject may include: (1) increased granulation tissue formation (i.e., faster healing), (2) reduced detachment force required to remove the dressing (i.e., easy to use, less pain) during dressing changes), (3) reduced dressing time (ie easy to use), and / or (4) reduced risk of maceration of the periphery during treatment, any or all of which may make it possible the 7-day dressing (versus 48-hour dressing changes), increased adherence to therapy and reduced care costs. Other objectives, advantages and a preferential way of manufacturing and using the claimed subject can be better understood with reference to the attached drawings together with the detailed description below of the illustrative modalities. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] [0017] Figure 1 is a functional block diagram of an exemplary modality of a therapy system that can provide tissue treatment according to this specification;
[0018] [0018] Figure 2 is an assembly view of an example of a dressing that illustrates additional details that can be associated with some exemplary modalities of the therapy system in Figure 1;
[0019] [0019] Figure 3 is a schematic view of an exemplary configuration of fluid restrictions in one layer that can be associated with some modalities of the dressing in Figure 2;
[0020] [0020] Figure 4 is an assembly view of another example of a dressing that illustrates additional details that can be associated with some exemplary modality of the therapy system of Figure 1;
[0021] [0021] Figure 5 is a schematic view of an exemplary configuration of openings in a layer that can be associated with some modalities of the dressing in Figure 4;
[0022] [0022] Figure 6 is a schematic view of the example layer of Figure 5 superimposed on the example layer of Figure 3;
[0023] [0023] Figure 7 is a schematic view of another example of a layer that can be associated with some modalities of a dressing;
[0024] [0024] Figure 8 and Figure 9 illustrate other exemplary configurations of fluid restrictions that can be associated with some types of dressing layers in Figure 2 or Figure 4;
[0025] [0025] Figure 10 is an assembly view illustrating an example of a tissue interface that can be associated with some modalities of the therapy system of Figure 1;
[0026] [0026] Figure 11 is a perspective view of another exemplary configuration of layers that can be associated with some modalities of a dressing in the therapy system of Figure 1;
[0027] [0027] Figure 12 is a partial sectional view of another exemplary configuration of layers that can be associated with some modalities of a dressing in the therapy system of Figure 1;
[0028] [0028] Figure 13 is a graphical representation of measurements of maximum detachment force (N) on day 7 after the application and removal of the dressing from each test and control dressing;
[0029] [0029] Figure 14 is a graphical representation of measurements of tissue in internal growth. The thickness (mm) is measured for each test dressing;
[0030] [0030] Figure 15 is an optical micrograph image that demonstrates the thickness of granulation tissue for each test and control dressing; and
[0031] [0031] Figure 16 is a graphical representation of Figure 15 that shows quantitative thickness of granulation tissue by morphometry for each test and control dressing. DESCRIPTION OF EXEMPLIFICATIVE MODALITIES
[0032] [0032] The following description of the exemplary modalities provides information that allows an element skilled in the art to make or use the subject presented in the attached claims, and may omit certain details already well known in the art. Therefore, the following detailed description should be considered as illustrative and not limiting.
[0033] [0033] The exemplary modalities can also be described with reference to spatial relationships between various elements or the spatial orientation of various elements depicted in the attached drawings in this document. Generally, such relationships or guidance consider a frame of reference consistent or relative to a patient receiving treatment. However, as should be recognized by those skilled in the art, this frame of reference is merely a descriptive resource rather than a strict prescription.
[0034] [0034] Figure 1 is a simplified functional block diagram of an exemplary embodiment of a therapy system 100 that can provide negative pressure therapy with instillation of optical treatment solutions into a tissue site according to this specification.
[0035] [0035] The term "tissue site", in this context, broadly refers to an injury, defect or other treatment target located on or within the tissue, including, but not limited to, a superficial wound, bone tissue, tissue adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons or ligaments. The term "tissue site" can also refer to areas of any tissue that are not necessarily injured or defective, but are instead areas where it may be desirable to add or promote additional tissue growth. For example, negative pressure can be applied to a tissue site to grow additional tissue that can be harvested and transplanted. A superficial wound, as used in this document, is a wound on the surface of a body that is exposed to the outer surface of the body, such as an injury or damage to the layers of the epidermis, dermis and / or subcutaneous. Superficial wounds can include ulcers or closed incisions, for example. A superficial wound, as used herein, does not include injuries to an intra-abdominal cavity. An injury can include chronic, acute, traumatic, subacute and open injuries due to dehiscence, partial thickness burns, ulcers (such as diabetic, pressure or ulcers due to venous insufficiency), flaps and grafts, for example.
[0036] [0036] Therapy system 100 may include a negative pressure source or supply, such as a negative pressure source 102, a dressing 104, a fluid container, such as a container 106, and a regulator or controller, such as a controller 108 , for example. In addition, therapy system 100 may include sensors for measuring operating parameters and providing controller 108 indicative of operating parameters. As shown in Figure 1, for example, therapy system 100 may include a pressure sensor 110, an electrical sensor 112 or both coupled to controller 108. As illustrated in the example in Figure 1, dressing 104 may comprise or consist essentially of one or more dressing layers, such as a fabric interface 114, a covering 116, or both in some embodiments.
[0037] [0037] Therapy system 100 may also include a source of instillation solution, such as saline, for example. For example, a source of solution 118 can be fluidly coupled to dressing 104, as illustrated in the exemplary embodiment of Figure 1. The source of solution 118 can be fluidly coupled to a source of positive pressure, such as the source of pressure positive 120, to a negative pressure source, such as negative pressure source 102, or both in some embodiments. A regulator, such as an instillation regulator 122, can also be fluidly coupled to the solution source 118 and dressing 104 to ensure the proper dosage of instillation solution to a tissue site. For example, instillation regulator 122 may comprise a piston that can be pneumatically actuated by the negative pressure source 102 to extract the instillation solution from the solution source during the negative pressure interval and to instill the solution into a dressing during an interval ventilation. In addition or alternatively, controller 108 can be coupled to negative pressure source 102, positive pressure source 120 or both to control the dosage of instillation solution to a tissue site. In some embodiments, the instillation regulator 122 can be fluidly coupled to the negative pressure source 102 via dressing 104 as shown in the example in Figure 1.
[0038] [0038] Some components of the therapy system 100 can be housed or used in conjunction with other components, such as sensors, processing units, alarm indicators, memory, database, software, display devices or user interfaces that additionally facilitate therapy. For example, in some embodiments, the negative pressure source 102 can be combined with the solution source 118, controller 108 and other components in a therapy unit.
[0039] [0039] Generally, the components of the therapy system 100 can be coupled directly or indirectly. For example, the negative pressure source 102 can be coupled directly to container 106, and can be indirectly coupled to dressing 104 through container 106. The coupling can include fluid, mechanical,
[0040] [0040] A distribution component is preferably detachable, and can be disposable, reusable or recyclable. Dressing 104 and container 106 are illustrative elements of delivery components. A fluid conductor is another illustrative example of a distribution component. A "fluid conductor", in this context, broadly includes a tube, pipe, hose, conduit or other structure with one or more lumen or open paths adapted to carry a fluid between two ends. Typically, a tube is an elongated cylindrical structure with some flexibility, but the geometry and stiffness can vary. In addition, some fluid conductors can be molded or otherwise integrally combined with other components. Distribution components may also include or comprise interfaces or fluid ports to facilitate the coupling and decoupling of other components, including sensors and data communication devices. In some embodiments, for example, a dressing interface may facilitate the coupling of a fluid conductor to dressing 104. For example, such a dressing interface may be a SENSAT.R.A.C. ™ block available from KCI in San Antonio, Texas.
[0041] [0041] A negative pressure supply, such as the negative pressure source 102, can be an air reservoir at a negative pressure, or it can be a manual or electrically powered device, such as a vacuum pump, a suction pump, a wall suction port available in many health facilities or a micro pump, for example. “Negative pressure” refers, in general, to a pressure less than a local ambient pressure, such as the ambient pressure in a local environment outside a sealed therapeutic environment. In many cases, the local ambient pressure can also be the atmospheric pressure at which a tissue site is located. Alternatively, the pressure may be less than a hydrostatic pressure associated with a tissue at the tissue site. Unless otherwise stated, the pressure values set out in this document are gauge pressures. References to increases in negative pressure typically refer to a decrease in absolute pressure, while decreases in negative pressure typically refer to an increase in absolute pressure. Although the amount and nature of negative pressure applied to a tissue site may vary according to therapeutic requirements, the pressure is generally low vacuum, commonly called a gross vacuum between -5 mm Hg (-667 Pa ) and -500 mm Hg (-66.7 kPa). Common therapeutic ranges are between -50 mm Hg (-9.9 kPa) and -300 mm Hg (-39.9 kPa).
[0042] [0042] Container 106 is representative of a container, canister, bag or other storage component, which can be used to manage exudates and other fluids extracted from a tissue site. In many environments, a rigid container may be preferred or required to collect, store and dispose of fluids. In other environments, fluids can be disposed of properly without storing a rigid container, and a reusable container can reduce residual waste and costs associated with negative pressure therapy.
[0043] [0043] A controller, such as controller 108, may be a microprocessor or computer programmed to operate one or more components of the therapy system 100, such as the negative pressure source 102. In some embodiments, for example, controller 108 may be a microcontroller, which generally comprises an integrated circuit containing a processor core and a memory programmed to directly or indirectly control one or more operating parameters of the therapy system 100. Operating parameters may include the power applied to the power source. negative pressure 102, the pressure generated by the negative pressure source 102 or the pressure distributed to the tissue interface 114, for example. Controller 108 is preferably also configured to receive one or more input signals, such as a feedback signal, and programmed to modify one or more operating parameters based on the input signals.
[0044] [0044] Sensors, such as pressure sensor 110 or electrical sensor 112, are generally known in the art as any operable device to detect and measure a phenomenon or physical property, and generally provide a signal indicating the phenomenon or property that is detected or measured. For example, pressure sensor 110 and electrical sensor 112 can be configured to measure one or more operating parameters of therapy system 100. In some embodiments, pressure sensor 110 can be a transducer configured to measure pressure over a path pneumatic and convert the measurement into a sign indicating the measured pressure. In some embodiments, for example, pressure sensor 110 may be a piezo-resistive voltage gauge. The electrical sensor 112 can optionally measure operating parameters of the negative pressure source 102, such as voltage or current in some embodiments. Preferably, the signals from the pressure sensor 110 and the electrical sensor 112 are suitable as an input signal to controller 108, but some signal conditioning may be appropriate in some embodiments. For example, the signal may need to be filtered or amplified before it can be processed by the controller
[0045] [0045] The fabric interface 114 can, in general, be adapted to contact a fabric location. The fabric interface 114 can be partially or completely in contact with the fabric location. If the tissue site is a wound, for example, the tissue interface 114 can partially or completely fill the wound, or it can be placed over the wound. The fabric interface 114 can take many forms and have more than one layer in some embodiments. The fabric interface 114 can also have many sizes, shapes or thicknesses depending on a variety of factors, such as the type of treatment being implemented or the nature and size of a fabric location. For example, the size and shape of the fabric interface 114 can be adapted to the depth contours and irregularly shaped fabric locations.
[0046] [0046] In some embodiments, coverage 116 can provide a barrier and bacterial protection from physical trauma. The cover 116 can be constructed from and a material that can reduce evaporative losses and provide a fluid seal between two components or two environments, such as between a therapeutic environment and a local external environment. The cover 116 can be, for example, a film or elastomeric membrane that can provide an adequate seal to maintain a negative pressure in a tissue location for a given source of negative pressure. Coverage 116 may have a high rate of mixture and vapor transmission (MVTR) in some applications. For example, MVTR can be at least 300 g / m2 for twenty-four hours in some modalities. In some exemplary embodiments, cover 116 may be a polymeric surgical field, such as a polyurethane film, which is permeable to water vapor, but impermeable to liquid. Such surgical drapes have a thickness in the range of 25 to 50 microns. For permeable materials, the permeability should, in general, be low enough for a desired negative pressure to be maintained. The cover 116 may comprise, for example, one or more of the following materials: hydrophilic polyurethane; cellulosic; hydrophilic polyamides; polyvinyl alcohol; polyvinyl pyrrolidone; hydrophilic acrylics; hydrophilic silicone elastomers; an INSPIRE 2301 material from Coveris Advanced Coatings of Wrexham, United Kingdom which has, for example, an MVTR (inverted cup technique) of 14400 g / m2 / 24 hours and a thickness of about 30 microns; a thin, uncoated polymeric surgical field; natural rubbers; polyisoprene; styrene butadiene rubber; chloroprene rubber; polybutadiene; nitrile rubber; butyl rubber; ethylene propylene rubber; ethylene propylene diene monomer; chlorosulfonated polyethylene; polysulfide rubber; polyurethane (PU); EVA film; copolyester; silicones; a silicone surgical field; a 3M Tegaderm® surgical field; a polyurethane (PU) surgical field, such as one available from Avery Dennison Corporation of Glendale, California; polyether block polyamide copolymer (PEBAX), for example, from Arkema, France; INSPIRE 2327; or other suitable material.
[0047] [0047] A fixing device can be used to fix the cover 116 to a fixation surface, such as undamaged skin, a joint or another cover. The fixing device can take many forms. For example, a fixation device can be a medically acceptable and pressure sensitive adhesive configured to attach the cover 116 to the epidermis around a tissue site, such as a superficial wound. In some embodiments, for example, some or all of the covers 116 may be coated with an adhesive, such as an acrylic adhesive, which can have a coating weight of between 25 to 65 grams per square meter (g.s.m.). Thicker adhesives, or combinations of adhesives, can be applied in some ways to improve sealing and reduce leakage. Other exemplary embodiments of a fixture may include a double-sided tape, paste, hydrocolloid, hydrogel, silicone gel or organogel.
[0048] [0048] Solution source 118 may also be representative of a container, canister, purse, bag or other storage component, which may provide a solution for instillation therapy. Solution compositions can vary according to a therapy described, but examples of solutions that may be suitable for some prescriptions include hypochlorite-based solutions, silver nitrate (0.5%), sulfur-based solutions, biguanides, solutions cationic and isotonic solutions.
[0049] [0049] The fluid mechanics of using a negative pressure source to reduce pressure on another component or location, such as within a sealed therapeutic environment, can be mathematically complex. However, the basic principles of fluid mechanics applicable to negative pressure and instillation therapy are, in general, well known to those skilled in the art, and the pressure reduction process can be described illustratively in this document as negative pressure “ delivery ”,“ distribution ”or“ generation ”, for example.
[0050] [0050] In general, exudates and other fluids flow towards the lower pressure along a fluid path. Thus, the term "downstream" typically implies something in a fluid path relatively closer to a source of negative pressure or further away from a source of positive pressure. On the other hand, the term “upstream” implies something relatively further away from a source of negative pressure or closer to a source of positive pressure. Similarly, it may be convenient to describe certain features in terms of fluid “inlet” or “outlet” in such a frame of reference. This guidance is, in general, assumed for the purpose of describing various features and components in this document. However, the fluid path can also be reversed in some applications (such as replacing a negative pressure source with a reduced pressure source) and this descriptive convention should not be interpreted as a limiting convention.
[0051] [0051] Figure 2 is an assembly view of an example of dressing 104 in Figure 1 that illustrates additional details that can be associated with some embodiments in which the fabric interface 114 comprises more than one layer. In the example of Figure 2, the fabric interface 114 comprises a first layer 205 and a second layer 210. In some embodiments, the first layer 205 can be arranged adjacent to the second layer 210. For example, the first layer 205 and the second layer 210 can be stacked so that the first layer 205 is in contact with the second layer
[0052] [0052] The first layer 205 comprises or consists, in general, essentially of a collector or a collector layer, which provides a means for collecting or distributing through the fabric interface 114 under pressure. For example, the first layer 205 can be adapted to receive negative pressure from a source and distribute negative pressure through multiple openings through the tissue interface 114, which can have the effect of collecting fluid from a tissue site and extracting the tissue. fluid towards the source. In some embodiments, the fluid path can be reversed or a secondary fluid path can be provided to facilitate fluid delivery, such as from an instillation solution source through the tissue interface 114.
[0053] [0053] In some illustrative modalities, the trajectories of the first layer 205 can be interconnected to improve the distribution or collection of fluids. In some illustrative embodiments, the first layer 205 may comprise or consist of a porous material that has interconnected fluid paths. For example, open cell foam, cross-linked foam, collections of porous tissue and other porous materials, such as gauze or felt, can in general include pores, edges and / or walls adapted to form interconnected fluid channels. Other suitable materials may include a 3D fabric (Baltex, Muller, Heathcoates), non-woven (Libeltex, Freudenberg), a 3D polymeric structure (molded polymers, embossed and formed films and films fused together [Supracore]), and mesh, for example. Liquids, gels and other foams can include or be cured to include openings and fluid paths. In some embodiments, the first layer 205 may additionally or alternatively comprise projections that form interconnected fluid paths. For example, the first layer 205 can be shaped to provide surface projections that define interconnected fluid paths. Any or all of the surfaces of the first 205 layer can be irregular, granular or serrated.]
[0054] [0054] In some embodiments, the first layer 205 may comprise or consist essentially of a reticulated foam that has pore sizes and free volume that may vary according to the needs of a prescribed therapy. For example, a cross-linked foam that has a free volume of at least 90% may be suitable for many therapy applications, and a foam that has an average pore size in the range of 400 to 600 microns may be particularly suitable for some types of therapy. The tensile strength of the first layer 205 can also vary according to the needs of a prescribed therapy. For example, the tensile strength of a foam can be increased to instill topical treatment solutions. The 25% compression load deflection of the first layer 205 can be at least 0.025 kgf / cm2 (0.35 pounds per square inch), and the 65% compression load deflection can be at least 0.030 kgf / cm2 ( 0.43 pounds per square inch). In some embodiments, the tensile strength of the first layer 205 can be at least 0.70 kgf / cm2 (10 pounds per square inch). The first layer 205 can have a tensile strength of at least 0.17 kgf / cm2 (2.5 pounds per square inch). In some embodiments, the first layer 205 may be a foam comprised of polyols, such as polyester or polyether, isocyanate, such as toluene diisocyanate, and polymerization modifiers, such as amines and tin compounds. In a non-limiting example, the first layer 205 may be a cross-linked polyurethane foam, as used in the GRANUFOAM ™ dressing or V.A.C. VERAFLO ™, both available from KCI in San Antonio, Texas.
[0055] [0055] The first layer 205 generally has a first flat surface and a second flat surface opposite the first flat surface. The thickness of the first layer 205 between the first flat surface and the second flat surface can also vary according to the needs of a described therapy. For example, the thickness of the first layer 205 can be decreased to relieve stress on other layers and to reduce tension in the peripheral tissue. The thickness of the first layer 205 can also affect the formability of the first layer 205. In some embodiments, a thickness in the range of about 5 millimeters to 10 millimeters may be suitable.
[0056] [0056] The second layer 210 may comprise or consist essentially of a means for controlling or managing the flow of fluid. In some embodiments, the second layer 210 may comprise or consist essentially of an elastomeric liquid impermeable material. For example, second layer 210 may comprise or consist of a polymeric film. The second layer 210 may also have a smooth or matte surface texture in some embodiments. A glossy or shiny finish better than or equal to a B3 grade according to the SPI (Society of the Plastics Industry) standards can be particularly advantageous for some applications. In some embodiments, variations in surface height may be limited to acceptable tolerances. For example, the surface of the second layer may have a substantially flat surface with variations in height limited to 0.2 millimeters in one centimeter.
[0057] [0057] In some embodiments, the second layer 210 may be hydrophobic. The hydrophobicity of the second layer 210 may vary, but may have an angle of contact with water of at least ninety degrees in some embodiments. In some embodiments, the second layer 210 may have a water contact angle of no more than 150 degrees. For example, in some embodiments, the contact angle of the second layer 210 may be in a range of at least 90 degrees to about 120 degrees, or in a range of at least 120 degrees to 150 degrees. Water contact angles can be measured using any standard device. Although manual goniometers can be used to visually approximate contact angles, contact angle measuring instruments can often include an integrated system that involves a leveled stage, the liquid dropper, such as a syringe, camera and software designed for calculate contact angles more accurately and precisely among other things. Non-limiting examples of such integrated systems may include the FTÅ125, FTÅ200, FTÅ2000 and FTÅ4000 systems, all commercially available from First Ten Angstroms, Inc., of Portsmouth, VA, and the DTA25, DTA30 and DTA100 systems, all commercially available from from Kruss GmbH in Hamburg, Germany. Unless otherwise specified, the angles of contact with water in this document are measured using deionized and distilled water on a level sample surface for a sessile drop added from a height not greater than 5 cm in the air at 20 to 25ºC and 20 to 50% relative humidity. The contact angles reported in this document represent averages of 5 to 9 measured values, discarding both the highest and lowest measured values. The hydrophobicity of the second layer 210 can be further improved with a hydrophobic coating of other materials, such as silicones and fluorocarbons, as coated with a liquid or coated with plasma.
[0058] [0058] The second layer 210 may also be suitable for welding on other layers, including the first layer 205. For example, the second layer 210 can be adapted for welding on polyurethane foams with the use of heating, radio frequency welding (RF) or other methods to generate heat, such as ultrasonic welding. RF welding can be particularly suitable for more polar materials, such as polyurethane, polyamides, polyesters and acrylates. Polar sacrificial interfaces can be used to facilitate RF welding of less polar film materials, such as polyethylene.
[0059] [0059] The area density of the second layer 210 may vary according to a prescribed therapy or application. In some embodiments, an area density of less than 40 grams per square meter and an area density of about 20 to 30 grams per square meter can be particularly advantageous for some applications.
[0060] [0060] In some embodiments, for example, the second layer 210 may comprise or consist essentially of a hydrophobic polymer, such as a polyethylene film. The simple and inert polyethylene structure can provide a surface that interacts little, if any, with biological tissues and fluids, providing a surface that can encourage free flow of liquids and low adhesion, which can be particularly advantageous for many applications. Other suitable polymeric films include polyurethanes, acrylics, polyolefin (such as cyclic olefin copolymers), polyacetates, polyamides, polyesters, copolyesters, PEBAX block copolymers, thermoplastic elastomers, thermoplastic vulcanized, polyethers, polyvinyl alcohol, polypropylene, polypropylene, polypropylene, polypropylene, polypropylene, polypropylene, polypropylene, polypropylene. , silicones, fluoropolymers and acetates. A thickness between 20 microns and 100 microns can be suitable for many applications. Films can be clear, colored or printed. The most polar films suitable for lamination to a polyethylene film include polyamide, copolyesters, ionomers and acrylics. To assist in joining a polyethylene film and a polar film, bonding layers can be used, such as vinyl ethylene acetate, or modified polyurethanes. A methyl ethyl acrylate (EMA) film can also have suitable hydrophobic and welding properties for some configurations.
[0061] [0061] As illustrated in the example in Figure 2, the second layer 210 can have one or more fluid restrictions 220, which can be distributed evenly or randomly through the second layer 210. Fluid restrictions 220 can be bidirectional and pressure responsive . For example, each of the fluid restrictions 220 may, in general, comprise or consist essentially of an elastic passage that is not normally tensioned to substantially reduce the flow of liquid, and may expand or open in response to a pressure gradient. In some embodiments, fluid restrictions 220 may comprise or consist essentially of perforations in the second layer 210. Perforations may be formed by removing the second layer
[0062] [0062] For example, some modalities of fluid restrictions 220 may comprise or consist essentially of one or more grooves, slits or combinations of grooves and slits in the second layer 210. In some examples, fluid restrictions 220 may comprise or consist of linear slits that are less than 4 millimeters long and less than 1 millimeters wide. The length can be at least 2 millimeters, and the width can be at least 0.4 millimeters in some embodiments. A length of about 3 millimeters and a width of about 0.8 millimeters can be particularly suitable for many applications, and a tolerance of about 0.1 millimeters may also be acceptable. Such dimensions and tolerances can be achieved with a laser cutter, for example. Slits in such configurations can function as imperfect valves that substantially reduce the flow of liquid in a normally closed or resting state. For example, such slits can form a flow restriction without being completely closed or sealed. Slits may expand or open more widely in response to a pressure gradient to allow for increased liquid flow.
[0063] [0063] In the example of Figure 2, dressing 104 may additionally include a fixation device, such as an adhesive 240. Adhesive 240 may be, for example, a medically acceptable and pressure sensitive adhesive that extends around a periphery , a portion or the entire covering 116. In some embodiments, for example, adhesive 240 may be an acrylic adhesive that has a coating weight of between 25 to 65 grams per square meter (gsm). Thicker adhesives, or combinations of adhesives, can be applied in some ways to improve sealing and reduce leakage. In some embodiments, such a layer of adhesive 240 may be continuous or discontinuous. Discontinuities in adhesive 240 can be provided by openings or holes (not shown) in adhesive 240. The openings or holes in adhesive 240 can be formed after applying adhesive 240 or by coating adhesive 240 in patterns on a carrier layer , such as, for example, one side of the cover 116. The openings or holes in the adhesive 240 can be sized to improve the MVTR of the 104 in dressing in some exemplary embodiments.
[0064] [0064] As shown in the example of Figure 2, in some embodiments, dressing 104 may include a removable strip 245 to protect adhesive 240 prior to use. Removable strip 245 can also provide hardness to assist, for example, in the implantation of dressing 104. Removable strip 245 can be, for example, a casting paper, a film or polyethylene. In addition, in some embodiments, the removable strip 245 may be a polyester material, such as polyethylene terephthalate (PET), or similar polar semicrystalline polymer. The use of semicrystalline polar polymer for the removable strip 245 can substantially preclude the curling or other deformation of the dressing 104. For example, the semicrystalline polar polymer can be highly oriented and resistant to softening, swelling or other deformation that can occur when brought into contact with the components of dressing 104, or when subjected to temperature or environmental variations or sterilization. In addition, a release agent can be disposed on one side of the removable strip 245 which is configured to contact the second layer
[0065] [0065] Figure 2 also illustrates an example of a fluid conductor 250 and a dressing interface 255. As shown in the example of Figure 2, fluid conductor 250 can be a flexible tube, which can be fluidly coupled to one another. end to dressing interface 255. Dressing interface 255 can be an elbow connector, as shown in the example in Figure 2, which can be placed in an opening 260 in cover 116 to provide a fluid path between the fluid conductor 250 and the fabric interface
[0066] [0066] Figure 3 is a schematic view of an example of the second layer 210 that illustrates additional details that can be associated with some modalities. As shown in the example in Figure 3, fluid constraints 220 can each essentially consist of one or more linear slits that are about 3 millimeters long. Figure 3 further illustrates an example of a uniform distribution pattern of fluid restrictions 220. In Figure 3, fluid restrictions 220 are substantially coextensive with the second layer 210, and are distributed across the second layer 210 in a grid of rows. and parallel columns, in which the slits are mutually parallel to each other. In some embodiments, the rows can be spaced about 3 millimeters in the center, and fluid restrictions 220 in each row can be spaced about 3 millimeters in the center as illustrated in the example in Figure
[0067] [0067] One or more components of dressing 104 can be treated additionally with a microbial agent in some embodiments. For example, the first layer 205 may be a foam, mesh or nonwoven coated with a microbial agent. In some embodiments, the first layer may comprise antimicrobial elements, such as fibers coated with a microbial agent. Additionally or alternatively, some embodiments of the second layer 210 may be a polymer coated or mixed with a microbial agent. In other examples, fluid conductor 250 may be treated additionally or alternatively with one or more antimicrobial agents. Microbial agents can include, for example, metallic silver, PHMB, iodine or its complexes and mixtures, such as povidone iodine, metallic copper compounds, chlorhexidine or some combination of these materials.
[0068] [0068] Additionally or alternatively, one or more components can be coated with a mixture that can include citric acid and collagen, which can reduce biofilms and infections. For example, the first layer 205 may be a foam coated with a mixture.
[0069] [0069] The individual components of dressing 104 can be joined together or otherwise bonded together with a solvent or non-solvent adhesive, or with thermal welding, for example, without adversely affecting fluid management.
[0070] [0070] The cover 116, the first layer 205 and the second layer 210, or various combinations can be assembled before application or on site. For example, cover 116 can be laminated to first layer 205, and second layer 210 can be laminated to first layer 205 opposite cover 116 in some embodiments. The second layer 210 can provide a smooth surface opposite to the first layer 205. In some embodiments, one or more layers of the fabric interface 114 can be coextensive. For example, the second layer 210 can be cut flush with the edge of the first layer 205, exposing the edge of the first layer 205 as shown in the embodiment of Figure 2. In other embodiments, the second layer 210 can overlap the edge of the first layer 205. In some embodiments, dressing 104 may be provided as a single composite dressing. For example, the second layer 210 can be attached to the cover 116 to wrap the first layer 205,
[0071] [0071] In use, the removable strip 245 (if included) can be removed to expose the second layer 210, which can be placed inside, on, in or otherwise close to a fabric location, particularly a surface tissue and adjacent epidermis. The second layer 210 can be interposed between the first layer 205 and the tissue site and the adjacent epidermis, which can substantially reduce or eliminate adverse interaction with the first layer 205. For example, the second layer 210 can be placed on a wound superficial (including wound edges) and on an undamaged epidermis to prevent direct contact with the first layer 205. Treating a superficial wound or placing dressing 104 on a superficial wound includes placing dressing 104 immediately adjacent to the body surface or extend on at least a portion of the body's surface. The treatment of a superficial wound does not include placing dressing 104 entirely inside the body or totally under the body surface, such as placing a dressing inside the abdominal cavity. The cover 116 can be sealed on a fixation surface, such as peripheral epidermis to a tissue location, around the first layer 205 and the second layer
[0072] [0072] The geometry and dimensions of the fabric interface 114, cover 116 or both may vary to suit a particular application or anatomy. For example, a geometry or dimensions of the fabric interface 114 and cover 116 can be adapted to provide an effective and reliable seal against challenging anatomical surfaces,
[0073] Thus, dressing 104 in the example of Figure 2 can provide a sealed therapeutic environment close to a tissue site substantially isolated from the external environment, and the negative pressure source 102 can reduce pressure in the sealed therapeutic environment. Negative pressure in the sealed environment can compress the first layer 205 into the second layer 210, which can deform the surface of the second layer 210 to provide an irregular, granular or jagged profile that can induce macrotension and microtension at the tissue site in some embodiments. Negative pressure applied through the fabric interface 114 can also create a negative pressure differential across fluid constraints 220 on second layer 210, which can open fluid constraints 220 to allow exudate and other liquid movement through fluid constraints 220 in the first layer 205 and in the container 106. For example, in some embodiments in which fluid restrictions 220 may comprise perforations through the second layer 210, a pressure gradient through the perforations may tension the adjacent material of the second layer 210 and increase the dimensions of the perforations to allow the movement of liquid through them, similar to the operation of a duckbill valve.
[0074] [0074] In some embodiments, the first layer 205 may be hydrophobic to minimize retention or storage of liquid in dressing 104. In other embodiments, the first layer 205 may be hydrophilic. In an example in which the first layer 205 can be hydrophilic, the first layer 205 can also move the fluid away from a tissue site, while continuing to distribute negative pressure to the tissue site. The spreading properties of the first layer 205 can extract fluid from a tissue site by capillary flow or other spreading mechanisms, for example. An example of a hydrophilic first layer 205 is an open cell foam polyvinyl alcohol as a WHITEFOAM ™ V.A.C. available from KCI of San Antonio, Texas. Other hydrophilic foams can include those made of polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.
[0075] [0075] If negative pressure source 102 is removed or turned off, the pressure differential through fluid restrictions 220 can dissipate, allowing fluid restrictions 220 to return to a non-tensioned or resting state and prevent or reduce rate exudate or other movement of liquid to the tissue site through the second layer 210.
[0076] [0076] In some applications, a charge can also be placed between a fabric location and the second layer
[0077] [0077] Additionally or alternatively, the fabric interface 114 can be formed into strips suitable for use as bridges or to fill tunnel wounds, for example. Strips having a width of about 5 mm to 30 mm may be suitable for some modalities.
[0078] [0078] Additionally or alternatively, the second layer 210 may comprise reinforced fibers to increase its tensile strength, which can be advantageous for use in tunnel wounds.
[0079] [0079] Additionally or alternatively, the instillation solution or other fluid can be delivered to dressing 104, which can increase pressure at tissue interface 114. Increased pressure at tissue interface 114 can create a positive pressure differential across fluid restrictions 220 in second layer 210, which may open or expand fluid restrictions 220 from its resting state to allow the instillation solution or other fluid to be delivered to the tissue site.
[0080] [0080] Figure 4 is an assembly view of another example of dressing 104 in Figure 1 that illustrates additional details that can be associated with some embodiments in which the fabric interface 114 can comprise additional layers. In the example of Figure 4, the fabric interface 114 comprises a third layer 405 in addition to the first layer 205 and the second layer 210. In some embodiments, the third layer 405 may be adjacent to the second layer 210 opposite the first layer 205. The third layer 405 can be joined to second layer 210 in some embodiments.
[0081] [0081] The third layer 405 may comprise or consist essentially of a sealing layer formed from a soft and pliable material suitable for providing a fluid seal with a fabric location, and may have a substantially flat surface. For example, third layer 405 may comprise, without limitation, a silicone gel, a soft silicone, hydrocolloid, hydrogel, polyurethane gel, polyolefin gel, hydrogenated styrenic copolymer gel, a foamed gel, a soft closed cell, such as polyurethanes and polyolefins coated with an adhesive, polyurethane, polyolefin or hydrogenated styrenic copolymers. In some embodiments, the third layer 405 can have a thickness between about 200 microns (μm) and about 1000 microns (μm). In some embodiments, the third layer 405 can have a hardness between about 5 Shore OO and about 80 Shore OO. Additionally, the third layer 405 can be comprised of hydrophobic or hydrophilic materials.
[0082] [0082] In some embodiments, the third layer 405 may be a material coated with a hydrophobic element. For example, the third layer 405 can be formed by coating a spaced material, such as, for example, fabric, non-woven, molded or mesh extruded with a hydrophobic material. The hydrophobic material for the coating can be a soft silicone, for example.
[0083] [0083] The third layer 405 may have the periphery 410 surrounding or around an inner portion 415, and openings 420 arranged through the periphery 410 and the inner portion 415. The inner portion 230 may correspond to a surface area of the first layer 205 in some examples. The third layer 405 can have corners 425 and edges 430. The corners
[0084] [0084] The openings 420 can be formed by cutting or by applying a local or ultrasonic RF energy, for example, or by other suitable techniques to form an opening. The openings 420 can have a uniform distribution pattern, or can be randomly distributed on the third layer 405. The openings 420 on the third layer 405 can have many shapes, including circles, squares, stars, ovals, polygons, grooves, complex curves, shapes rectilinear, triangles, for example, or may have some combination of such shapes.
[0085] [0085] Each of the openings 420 can have uniform and similar geometric properties. For example, in some embodiments, each of the openings 420 may be circular openings having substantially the same diameter. In some embodiments, the diameter of each of the openings 420 can be between about 1 millimeter to about 50 millimeters. In other embodiments, the diameter of each of the openings 420 can be between about 1 millimeter to about 20 millimeters.
[0086] [0086] In other embodiments, the geometric properties of the openings 420 may vary. For example, the diameter of the openings 420 can vary depending on the position of the openings 420 in the third layer 405 as shown in Figure 4. In some embodiments, the diameter of the openings 420 in the periphery 410 of the third layer 405 may be larger than the diameter of the openings 420 in the inner portion 415 of the third layer 405. For example, in some embodiments, the openings 420 arranged at the periphery 410 may have a diameter between about 9.8 mm to about 10.2 mm. In some embodiments, the openings 420 arranged in the corners 425 can have a diameter between about 7.75 mm to about 8.75 mm. In some embodiments, the openings 420 arranged in the inner portion 415 can have a diameter between about 1.8 mm to about 2.2 mm.
[0087] [0087] At least one of the openings 420 in the periphery 410 of the third layer 405 can be positioned at the edges 430 of the periphery 410, and can have an open or exposed inner cut at the edges 430 which is in fluid communication in a lateral direction with the edges 430. The lateral direction can refer to a direction for the edges 430 and in the same plane as the third layer 405. As shown in the example in Figure 4, the openings 420 in the periphery 410 can be positioned close to or at the edges 430 and in communication fluid in a lateral direction with the edges 430. The openings 420 positioned close to or at the edges 430 can be spaced substantially equidistant around the periphery 410 as shown in the example in Figure 3. Alternatively, the spacing of the openings 420 nearby or at the edges 430 may be irregular.
[0088] [0088] As shown in the example of Figure 4, in some embodiments, the removable strip 245 can be attached or positioned adjacent to the third layer 405 to protect the adhesive 240 before use. In some embodiments, the removable strip 245 can have a surface texture that can be printed on an adjacent layer, such as the third layer 405. Additionally, a release agent can be disposed on one side of the removable strip 245 which is configured to enter in contact with the third layer 405.
[0089] [0089] Figure 5 is a schematic view of an exemplary configuration of the openings 420 that illustrates additional details that can be associated with some embodiments of the third layer 405. In some embodiments, the openings 420 shown in Figure 5 can be associated only with the portion interior 415. In the example of Figure 5, the openings 420 are, in general, circular and have a diameter of about 2 millimeters. Figure 5 also illustrates an example of a uniform distribution pattern of the openings 420 in the inner portion 415. In Figure 5, the openings 420 are distributed across the inner portion 415 in a grid of parallel rows and columns. In each row and column, the openings 420 can be equidistant from each other as illustrated in the examples in Figure 5. Figure 5 illustrates an exemplary configuration that can be particularly suitable for many applications, in which the openings 420 are separated about 6 millimeters apart. along each row and column with an offset of 3 millimeters.
[0090] [0090] Figure 6 is a schematic view of the exemplary third layer 405 of Figure 5 superimposed on the second layer 210 of Figure 3 which illustrates additional details that can be associated with some exemplary modalities of the fabric interface 114. For example, as illustrated in Figure 6, fluid restrictions 220 may be aligned, if overlapped, in register with, or otherwise fluidly coupled to, openings 420 in some embodiments. In some embodiments, one or more fluid restrictions 220 can be registered with openings 420 only in the inner portion 415, or only partially registered with openings 420. Fluid restrictions 220 in the example in Figure 6 are, in general, configured so that each fluid restriction 220 is registered with only one of the openings 420. In other examples, one or more fluid restrictions 220 can be registered with more than one of the openings 420. For example, any one or more fluid restrictions 220 can be a perforation or fenestration that extends through two or more openings
[0091] [0091] As illustrated in the example in Figure 6, the openings 420 can be sized to expose a portion of the second layer 210, fluid constraints 220 or both through the third layer 405. In some embodiments, one or more openings 235 may be sized to expose more than one of the fluid restrictions 220. For example, some or all of the openings 235 can be sized to expose two or three fluid restrictions 220. In some examples, the length of each of the fluid restrictions 220 can be substantially equal to the diameter of each of the openings
[0092] [0092] The individual components of dressing 104 in the example in Figure 4 can be joined or otherwise attached to each other with a solvent or non-solvent adhesive, or with thermal welding, for example, without adversely affecting fluid management . In addition, the second layer 210 or the first layer 205 can be coupled to the margin 435 of the third layer 405 in a suitable manner, as with a solder or an adhesive, for example.
[0093] [0093] The cover 116, the first layer 205, the second layer 210, the third layer 405 or various combinations can be assembled before application or on site. For example, cover 116 can be laminated to first layer 205, and second layer 210 can be laminated to first layer 205 opposite cover 116 in some embodiments. The third layer 405 can be coupled to the second layer 210 opposite the first layer 205 in some embodiments. In some embodiments, one or more layers of the fabric interface 114 may be coextensive. For example, the second layer 210, the third layer 405 or both can be cut flush with the edge of the first layer 205, exposing the edge of the first layer 205 as shown in the embodiment of Figure 4. In other embodiments, the second layer 210, the third layer 405 or both can overlap the edge of the first layer 205.
[0094] [0094] In use, the removable strip 245 (if included) can be removed to expose the third layer 405 of the example in Figure 4, which can be placed inside, on, in or otherwise close to a fabric location , particularly, to a site of surface tissue and the adjacent epidermis. The third layer 405 and the second layer 210 can be interposed between the first layer 205 and the tissue site, which can substantially reduce or eliminate adverse interaction with the first layer 205. For example, the third layer 405 can be placed in a superficial wound (including wound edges) and an undamaged epidermis to prevent direct contact with the first layer 205. In some applications, the inner portion 415 of the third layer 405 may be positioned adjacent, close to or covering a tissue site. In some applications, at least some portion of the second layer 210, fluid constraints 220 or both can be exposed to a tissue site through the third layer
[0095] [0095] Removing the removable strip 245 in the example in Figure 4 can also expose the adhesive 240 and the cover 116 can be attached to a fixation surface, such as peripheral epidermis, to a tissue location, around the first layer 205 and the second layer 210. For example, adhesive 240 can be in fluid communication with a fixing surface through openings 420 in at least the periphery 410 of third layer 405. Adhesive 240 can also be in fluid communication with edges 430 through the openings 420 exposed at the edges 430.
[0096] [0096] Once the dressing 104 is in the desired position, the adhesive 240 can be pressed through the openings 420 to attach the dressing 104 to the fixing surface. The openings 420 at the edges 430 may allow the adhesive 240 to flow around the edges 430 to improve the adhesion of the edges 430 to a fixing surface.
[0097] [0097] In some embodiments, the openings or holes in the third layer 405 can be sized to control the amount of adhesive 240 in fluid communication with the openings 420. For a given geometry of the corners 425, the relative sizes of the openings 420 can be configured to maximize the surface area of adhesive 240 exposed and in fluid communication through openings 420 in corners 425. For example, as shown in Figure 3, edges 430 can cross at a substantially right angle, or about 90 degrees, to define corners 425. In some embodiments, corners 425 can have a radius of about 10 millimeters. Additionally, in some embodiments, three of the openings 420 that have a diameter between about 7.75 mm to about 8.75 mm can be positioned in a triangular configuration at the corners 425 to maximize the exposed surface area for the adhesive 240. In other embodiments, the size and number of openings 420 in corners 425 can be adjusted as needed, depending on the chosen geometry of corners 425, to maximize the exposed surface area of adhesive 240. Additionally, openings 420 in corners 425 can be accommodated completely within the third layer 405, substantially precluding fluid communication in an outer lateral direction towards the corners 425. The openings 420 in the corners 425 that are housed completely within the third layer 405 can substantially preclude the fluid communication of the adhesive 240 with the exterior of the corners 425, and can provide improved handling of dressing 104 during implantation in a lo fabric lime. In addition, the outside of corners 425 which is substantially free of adhesive 240 can increase the flexibility of corners 425 to improve comfort.
[0098] [0098] In some embodiments, adhesive bond strength 240 may vary in locations other than dressing 104. For example, adhesive 240 may have lower bond strength in locations adjacent to third layer 405 where openings 420 are relatively larger , and may have a higher bond strength where the openings 420 are smaller. Adhesive 240 with lower bond strength in combination with larger openings 420 can provide a bond comparable to adhesive 240 with upper bond strength in locations that have smaller openings
[0099] [0099] The geometry and dimensions of the fabric interface 114, cover 116 or both may vary to suit a particular application or anatomy. For example, a geometry or dimensions of fabric interface 114 and cover 116 can be adapted to provide an effective and reliable seal against challenging anatomical surfaces, such as an elbow or heel, in and around a tissue site. Additionally or alternatively, the dimensions can be modified to increase the surface area for the second layer 405 to improve the movement and proliferation of epithelial cells in a tissue site and reduce the likelihood of granulation tissue in internal growth.
[00100] [00100] Additionally, dressing 104 may allow reapplication or repositioning to reduce or eliminate leaks that may be caused by folds and other discontinuities in dressing 104 or in a tissue location. The ability to rectify leaks can increase the reliability of therapy and reduce energy consumption in some modalities.
[00101] [00101] Thus, dressing 104 in the example in Figure 4 can provide a sealed therapeutic environment close to a tissue site substantially isolated from the external environment, and the negative pressure source 102 can reduce pressure in the sealed therapeutic environment. The third layer 405 can provide an effective and reliable seal against challenging anatomical surfaces, such as an elbow or heel, in and around a tissue site. Additionally, dressing 104 may allow reapplication or repositioning to correct air leaks caused by folds and other discontinuities in dressing 104, for example. The ability to rectify leaks can increase the effectiveness of therapy and reduce energy consumption in some modalities.
[00102] [00102] If not already configured, dressing interface 255 can be arranged over opening 260 and attached to cover 116. Fluid conductor 250 can be fluidly coupled to dressing interface 255 and negative pressure source 102.
[00103] [00103] The negative pressure applied through the fabric interface 114 can create a negative pressure differential through fluid restrictions 220 in the second layer 210, which can open or expand fluid restrictions 220. For example, in some embodiments in which fluid restrictions 220 may comprise substantially closed perforations through the second layer 210, a pressure gradient through the perforations may tension the adjacent material of the second layer 210 and increase the dimensions of the perforations to allow liquid movement through them, similar to operation of a duckbill valve. Opening fluid restrictions 220 may allow exudate and other movement of liquid through fluid restrictions 220 in first layer 205 and container 106. Changes in pressure can also cause first layer 205 to expand and contract, and 435 inner edge can protect the epidermis from irritation. The second layer 210 and the third layer 405 can also substantially reduce or prevent tissue exposure to the first layer 205, which can inhibit tissue growth within the first layer 205.
[00104] [00104] If the negative pressure source 102 is removed or turned off, the pressure differential through fluid restrictions 220 can dissipate, allowing fluid restrictions 220 to close and prevent exudate and other liquid from returning to the location of fabric through the second layer 210.
[00105] [00105] In some applications, a charge can also be placed between a fabric location and the third layer
[00106] [00106] Additionally or alternatively, the instillation solution or other fluid can be delivered to dressing 104, which can increase pressure at tissue interface 114. Increased pressure at tissue interface 114 can create a positive pressure differential across fluid restrictions 220 in second layer 210, which may open or expand fluid restrictions 220 from its resting state to allow the instillation solution or other fluid to be delivered to the tissue site.
[00107] [00107] Figure 7 is a top view of another example of the third layer 405, illustrating additional details that can be associated with some modalities. As shown in the example in Figure 7, the third layer 405 may have one or more elastomeric valves 705 instead of or in addition to the openings 420 in the inner portion 415. The valves 705 can be included in the third layer 405 in addition to or instead of the second layer
[00108] [00108] Figure 8 and Figure 9 illustrate other example configurations of the 705 valves, in which the 705 valves generally comprise a combination of crossed grooves or transverse grooves.
[00109] [00109] Figure 10 is an assembly view of another example of the fabric interface 114 of Figure 1. In the example of Figure 10, the second layer 210 is arranged adjacent to both sides of the first layer 205. In some embodiments, for example for example, the second layer 210 can be laminated or otherwise mechanically joined to both sides of the first layer 205. Additionally or alternatively, the third layer 405 can be arranged adjacent to one or more sides of the first layer 205 or can be arranged adjacent to the second layer 210, as shown in the example of Figure 10. In some embodiments, the third layer 405 may form a sleeve or envelope around the first layer 205, the second layer 210 or both.
[00110] [00110] Figure 11 is a perspective view of another exemplary configuration of the first layer205 and the second layer 210. In an example of Figure 11, the second layer 210 can form a sleeve around the first layer
[00111] [00111] Figure 12 is a partial section view of another exemplary configuration of the first layer and the second layer 210. In the example of Figure 12, the second layer 210 can form an envelope around the first layer 205. For example, the second layer 210 can be arranged on two sides of the first layer205, and the edges can be mechanically coupled together around the first layer 205 to form an envelope. The exemplary configuration of Figure 12 can be used in combination with or instead of other configurations of the first layer 205 and the second layer 210 described above.
[00112] [00112] The systems, devices and methods described in this document can provide significant advantages over previous dressings. For example, some dressings for negative pressure therapy may require time and skill to be sized and applied appropriately to achieve a good fit and seal. In contrast, some modalities of dressing 104 provide a negative pressure dressing that is simple to apply, reducing the time of application and removal. In some embodiments, for example, dressing 104 can be a completely negative negative pressure therapy dressing that can be applied to a tissue site (including in the periphery) in one step, without being cut to size, while still providing or enhancing many benefits of other negative pressure therapy dressings that require scaling. Such benefits may include good piping, beneficial granulation, protection of peripheral tissue from maceration, protection of the tissue site from flaking materials and a high seal and low trauma bond. These characteristics can be particularly advantageous for surface wounds having moderate and deep and medium to high levels of exudates. Some modalities of dressing 104 may remain in the tissue site for at least 5 days, and some modalities may remain for at least 7 days. Antimicrobial agents in dressing 104 can extend the useful life of dressing 104 by reducing or eliminating infection risks that can be associated with extended use, particularly when using infected or highly exuding wounds. Examples
[00113] [00113] Some of the advantages associated with the systems, devices, and methods described in this document can be further demonstrated by the following non-limiting examples.
[00114] [00114] Example 1 - Dressing evaluation in a full-thickness swine model of excision wounds
[00115] [00115] Objective
[00116] [00116] The main objective of this study was to evaluate a modality of a dressing having the characteristics described above (called "GM" for study purposes), in conjunction with V.A.C.® and V.A.C. VERAFLO ™ therapy compared to V.A.C.® Therapy with traditional GRANUFOAM ™ dressing and other Wound Care dressings
[00117] [00117] Test and Control Articles Test Article 1 (TA) Description Dressing GM Size 10 cm x 8 cm foam with 12.5 cm x 11 cm margin Store- Test article stored between 15ºC and 30ºC (59ºF ment and 86ºF). Control Article 1 (CA1) Description GRANUFOAM ™ V.A.C.® Dressing Size ~ 7.5cm x 3cm (cut to fit larger piece) Store- Control article stored between 15ºC and 30ºC (59ºF and 86ºF). Control Article 2 (CA2) Description TIELLE ™ advanced non-adhesive wound dressing (AWD)
[00118] [00118] Animal Model
[00119] [00119] This study was conducted using the animal model highlighted below: Species Sus scrofa scrofa (Porcine) Breed 1/2 Duroc, 1/4 cross of Landrace, 1/4 Yorkshire Source Oak Hill Genetics, Ewing, IL, USA Age at Suitable for weight Procedure Weight 50 to 70 kg or alternative weights as approved by the Study Director Gender Female (nulliparous and not pregnant) Number of 8 + 0 animal reserve
[00120] [00120] Study Project
[00121] [00121] Table 1. Study Design Gru- Nú- Number of AWD Alte Locations- Test of maximum number of NPWT Maximum rations Peel- Maximum Injury Program (Locations in the ment, based on Ani- Excisants by Healing- Evaluate - Eutana plus Raised in Animal Animal) tivo tion sia Dia 0 Visual,
[00122] [00122] TEWL = analysis of transepidermal water loss using Delfin moisture meter; AWD = Advanced Wound Dressing
[00123] [00123] Table 2. Description of Treatment Regimens and Dressings Number of Treatment Test Material Therapy Therapy / Treats Abbreviation ment 1 TANPTa TA Therapy V.A.C.® Continuous 2 TANPTIa TA VERAFLO ™ V.A.C. with saline solution 3 NPT CA1 Therapy V.A.C.® Continuous 4 AWD CA2 None 5 NPTI CA3 VERAFLO ™ V.A.C.com saline a With conductive threads placed on top in intact skin under dressing as appropriate
[00124] [00124] Surgical Procedures
[00125] [00125] Exciting Injury Creation - Day 0
[00126] [00126] The initial pilot animal (Group 1) subjected to all therapy and wound creation prior to the scheduling of procedures in the additional animals in Groups 2 and 3. Up to Ten (10) Exciting Full Skin Thickness Wounds (~ 3 x 7.5 cm) were created in each animal (up to 5 wounds on each side of the spine) with the aid of a sterile model. There was spacing between each of the wounds (approximately 6 cm or more from the edge of the wound to the edge of the wound between adjacent wounds, and sufficient spacing between all wounds to provide sufficient space to properly place the dressings and the surgical field. length of the animal's back does not provide enough space for 10 wounds and dressings (determined on Day 0) so 8 wounds (4 on each side of the spine) would be created. A scalpel blade was used to surgically create the wound below the layer subcutaneous fascial layer (just above the muscle) but without causing any rupture in it. If the rupture of the subcutaneous fascial layer occurs, it was documented in the study records. Care was taken during the creation of the wound to avoid damaging the perimeter of the wound. wounds were prepared in two spine columns with efforts made to keep the columns between the tips of the shoulders and the tuberosity coccygeal. Direct pressure with sterile gauze was used to obtain hemostasis. In the case of excessive bleeding that does not subsidize with direct pressure, a hemostat was used to staple the bleeding source. Injury sites were kept gauze moistened with sterile 0.9% saline solution during the creation of other wounds. The injuries were photographed.
[00127] [00127] Application of Dressings and Negative Pressure Therapy
[00128] [00128] After creating wounds (Day 0), all wounds received a Test or Control Article. On Day 4 (Group 3 only), those wounds submitted to dressing removal received a Test or Control Article.
[00129] [00129] On the designated dressing change day (after detachment test, TEWL, visual observations and photographs), the periphery area was cleaned with a cloth with gauze soaked with 0.9% sterile saline and allowed to dry. The dressings were applied to the individual injury sites by a randomization scheme.
[00130] [00130] An adhesive such as benzoin was placed on the skin that surrounds the entire perimeter of the test article edges, regardless of the type of dressing for a particular wound, so that the periphery area was framed with adhesive leaving a perimeter of ~ 1 cm of benzoin-free periphery. This means that the skin with immediate periphery cannot have a benzoin patch applied since this can affect the EpiD readings. The patch was placed on the skin in any area that the V.A.C.® Surgical Field was applied. Alternatively (or in addition), Hollister (a medical grade silicone adhesive) has been applied as an extra adhesive to help maintain a seal.
[00131] [00131] For the test article injury pair (test article with V.A.C.® Therapy), and / or the test article with V.A.C. In VERAFLO ™ Therapy wounds (test article using VAC VERAFLO ™ Therapy with saline), a pair of electrodes (for example, aluminum foil or wire) was applied so that it rested in the periphery area (under article test, but on top of skin with periphery).
[00132] [00132] As applicable, the skin under the foam bridge strips was covered with Surgical Field V.A.C.® to protect it. Each bridged wound group was covered with the V.A.C.® Surgical Field included in the dressing kit, a hole will be made in the surgical field and a SENSAT.R.A.C. ™ Block or a V.A.C. Block VERAT.R.A.C. ™ (as applicable) was fixed directly above the hole in accordance with the instructions for use (IFU). Each of the blocks was framed with Surgical Field V.A.C.® along each side to keep them in place and ensure that there was a seal.
[00133] [00133] A V.A.C.ULTA ™ unit was present in the surgical apparatus on the day of the wound creation and was properly connected to each block to verify that each wound group was properly sealed after application.
[00134] [00134] To check the seal around the wounds, negative pressure injury therapy (NPWT) started at a continuous vacuum pressure of -125 mmHg using the CHECK ™ sealing function on the V.A.C.ULTA ™ Unit. Upon verification of an appropriate seal, the V.A.C.ULTA ™ unit was disconnected and this procedure was repeated as applicable. After checking all seals, additional layers of Surgical Field V.A.C.® were placed around the edges to reinforce the seals and prevent leaks.
[00135] [00135] For wounds receiving V.A.C. Therapy VERAFLO ™, the Fill Aid feature was used to determine the volume of fluid (ie, saline) required to saturate the dressings on paired wounds. These determinations were made for wound pairs at each dressing change, as appropriate. V.A.C. Therapy VERAFLO ™ NPWT was started at a continuous vacuum pressure of
[00136] [00136] The entire area covered with Surgical Field V.A.C.® was covered with surgical field with a tear-resistant mesh (for example, organza material) attached with Surgical Field V.A.C.®, Elastikon® or equivalent to prevent displacement of the dressings.
[00137] [00137] Provisional Bandage Change - Day 4 Group 3 Only
[00138] [00138] Resistance readings below the dressings were taken. The detachment strength test for wounds was performed on one wound from each treatment pair. The dressings were removed by hand / for the other half of each wound pair, except for the dressings that needed to remain in place (ie TANPT and TANPTI (n = 2 animals)). Injury assessments were performed (as applicable) and photographs taken.
[00139] [00139] Detachment Test and Observations
[00140] [00140] The detachment strength test was performed on one wound from each treatment pair (same wounds as dressing change, if applicable). For wounds where the dressing was removed, TEWL was performed, wound assessments were performed and photographs were taken.
[00141] [00141] For Groups 1 & 2, (Day 4), the detachment strength test, TEWL and assessments were performed on 5 injuries. The remaining 5 wounds were collected with dressings locally for processing and histopathology evaluation.
[00142] [00142] For Group 3 (Day 7), detachment strength test, TEWL and assessments were performed on 5 injuries. The remaining 5 wounds were collected with dressings locally for processing and histopathology evaluation.
[00143] [00143] The detachment force test was performed on a tilting operation table. The detachment strength test was performed using a device that detaches from the edge of test material while measuring the force that is required to detach the dressing from the wound at an angle of ~ 180º to the detachment tester. A digital protractor was used to confirm the angle. The peel strength values indicate how easily the test materials can be removed from the wound bed. The removal of the test materials was performed using a 20N Shimpo Digital Force Gauge that was mounted on a Shimpo Motorized Test Stand and controlled via a computer equipped with Labvista.
[00144] [00144] The surgical field over the control articles for detachment test was carefully circumscribed with a scalpel, taking care not to disrupt the internal growth of tissue on the sides of the dressing. In treatments with the test article for detachment testing, a scalpel was used to remove excess dressing that was not in contact with the wound. This was done by cutting the dressing along the sides, bottom and top where the wound margins are visible after negative pressure therapy. The central end of the bandage or bandage flap was attached to the force gauge with the clip (no circumscription of the bandage will be performed). The dressing was then pulled from the wound (central to lateral) at a constant rate from a central to lateral direction. After the detachment force measurements were made, evaluations were performed. The continuous detachment force readings were recorded through Labvista through the Force Gauge and saved for each injury. After the detachment test, the dressings were kept for analysis of the tissue that remains inside the dressing.
[00145] [00145] Figure 13 demonstrates the results of maximum detachment force measurements (N) on day 7 after applying the dressing and removing test articles (called “TANPT” and TANPTI) and control dressings. As can be seen, the test article with and without V.A.C. VERAFLO ™ required significantly less detachment strength.
[00146] [00146] After the detachment strength test and TEWL measurements, two biopsy punctures (5mm, or not exceeding 8mm each) were collected from the center of each wound as applicable.
[00147] [00147] Loss of Transepidermal Water
[00148] [00148] The moisture level determination at the dressing-skin interface (intact) was performed using an EpiD Compact Moisture Meter from Delfin Technologies (Kuopio, Finland). This measurement was made immediately after the wound was created on Day 0, on the dressing change day (as applicable), and on completion prior to euthanasia. To measure the skin dielectric constant, the EpiD Compact instrument was used. On the day of wound creation (Day 0), four consecutive moisture measurements were taken from the intact skin on each animal that approached halfway between the wound and the edge of the wound block from which the test article and the wound dressings advanced were. On the day of dressing change and at completion (as applicable), four consecutive moisture measurements were collected. These measurements were repeated at each of the injury sites available for each animal. All measurements / data were recorded.
[00149] [00149] Injury Assessments
[00150] [00150] Gross Observations
[00151] [00151] Injury observations were made and documented in the dressing change and / or in the completion procedure as follows: • Injury bleeding - None, Negligible, Moderate or Significant. • Crude observations - Dry (opaque / not shiny), Moist (shiny in appearance), Wet (presence of fluid), Escara (fabric with dark and hardened appearance), Bark (removable yellow layer) and its location (or locations) in the injury site. • Discharge - None, Serous (thin, wet, clear) Serosanguineous (thin, light red to pink), Sanguine (thin, bright red), Purulent (opaque from brown to yellow, thin or thick).
[00152] [00152] Dressing and Fabric Retention
[00153] [00153] Dressing retention (small particles and large pieces) was evaluated following the removal of the dressing or detachment test. After removing the bandages from the wound, the bandage retention in the wound was visually assessed and documented. All dressings removed were visually evaluated for tissue retention and digitally photographed.
[00154] [00154] Figure 14 demonstrates that there was a significant reduction in internal tissue growth with TANPT and TANPTI.
[00155] [00155] Histopathology
[00156] [00156] If the wound sites were in 70% ethanol, they were immediately processed and if received in NBF wounds they were transferred to 70% ethanol for a period of time before further processing by standard Test Site procedures Histopathology. The wound site + dressings (if intact) were embedded in oversized paraffin blocks, the entire block site was cut transversely once at ~ 5 μm thick and the resulting slides stained with Hematoxylin and Eosin (H&E). Raw images were taken of the cut surface of the specimens before processing and soaking in paraffin. In order to accommodate the entire section of tissue with an unaffected skin margin on all sides, oversized blades were used.
[00157] [00157] The histopathological response was scored semi-quantitatively by a certified veterinary pathologist, on a scale of 1 to 5 where 1 = minimal, 2 = mild, 3 = moderate, 4 = notable and 5 = severe, except where otherwise specified. Microscopic evaluation of all stained sections for morphological changes to the wound including, but not limited to, character tissue and granulation thickness, amount of granulation tissue soaked in dressing (if possible), tissue inflammation, edema, vascularity (if possible), presence of bacteria, necrosis and other relevant factors as determined by the pathologist. The periphery area was evaluated for characteristics consistent with maceration as determined by the pathologist.
[00158] [00158] 2D photographs of individual injury sites
[00159] [00159] Two-dimensional (2-D) photographs of individual injury sites were taken at the following points in time: • Day 0 (newly created injuries) - all injuries • Day 4 (dressing change day or completion as applicable) after dressing removal and before applying new dressings - wounds awnings 2D photographs of the dressing just removed next to the wound were taken. • Day 7 after dressing removal and before euthanasia.
[00160] [00160] 2D photographs of the dressing just removed near the wound were taken.
[00161] [00161] Histopathological evaluation of individual injury sites
[00162] [00162] The optical micrograph images in Figure 15 demonstrate that TANPT had significantly more granulation than NPT and NPTI.
[00163] [00163] Additionally, Figure 16 is a graphical representation that compares the thickness of granulation tissue from Day 7 between the test and the control treatments. TANPT and TANPTI showed significantly higher granulation tissue thickness.
[00164] [00164] Study Conclusions
[00165] [00165] The data demonstrates that the test article had surprisingly positive results, with improvements when combined V.A.C. VERAFLO ™. The V.A.C. Therapy test article VERAFLO ™ therapy performed superiorly because it shows an increase in the thickness of granulation tissue, a reduction in internal tissue growth, percentage of medical vascularization and epithelialization.
[00166] [00166] Additionally, on Day 7, all treatments with the test article showed significantly greater granulation tissue than NPT and NPTI. The percentage increase in depth of granulation using the test article (measured after a 7-day treatment period) was at least 75% for NPT and 200% for NPTI. No evidence of adverse events or safety concerns was found. Peripheral tissue moisture decreased with time (all treatment groups) reducing the risk of Maceration.
[00167] [00167] All treatments with the test article also showed surprising reductions in the internal growth of the tissue, as evidenced by the significant reductions in the detachment force. After 7 days of continuous V.A.C.® Therapy or VERAFLO ™ V.A.C. Therapy with no change in the dressing, a detachment force of less than 2N was required to remove the test article. Specifically, a 1.8N peel force was used to remove the TANPTI test article, and a 1.5N peel force was used to remove the TANPT test article. Comparing CA1 with V.A.C.® Therapy, the detachment force was reduced by 87% and 89%, respectively.
[00168] [00168] Although shown in some illustrative modalities, an element of common knowledge in the art will recognize that the systems, apparatus and methods described in this document are susceptible to various changes and modifications that fall within the scope of the attached claims. In addition, descriptions of various alternatives using terms such as "or" do not require mutual exclusivity at least if clearly required by the context, and the indefinite articles "one" or "one" do not limit the subject to a single case unless at least clearly required in the context. context.
[00169] [00169] Resources, elements and aspects described in the context of some modalities may also have been omitted, combined or replaced by alternative resources that serve the same, equivalent or similar purpose without departing from the scope of the invention defined by the attached claims. For example, one or more of the features of some layers can be combined with features of other layers to provide an equivalent function. Alternatively or in addition, one or more of the fluid restrictions 220 may have shapes similar to the formats described as exemplary for the 705 valves. In other examples, the second layer 210, the third layer 405 or some combination of the second layer 210 and the third layer 405 can be coupled to both sides of the first layer 205.
[00170] [00170] Components can also be combined or eliminated in various configurations for the purpose of sale, manufacture, assembly or use. For example, in some configurations, dressing 104, container 106 or both can be disposed of or separated from other components for manufacture or sale. In other exemplary configurations, components of dressing 104 may also be manufactured, configured, assembled or sold independently or as a kit.
[00171] [00171] The attached claims present innovative and inventive aspects of the novel matter described above, however the claims may also cover additional matters not specifically mentioned in detail. For example, certain features, elements or aspects can be omitted from the claims if they are not needed to distinguish innovative and inventive features from what is already known by an element of common knowledge in the art. Resources, elements and aspects described in the context of some modalities may also have been omitted, combined or replaced by alternative resources that serve the same, equivalent or similar purpose without departing from the scope of the invention defined by the attached claims

权利要求:
Claims (111)
[1]
1. DRESSING TO TREAT A FABRIC PLACE WITH NEGATIVE PRESSURE, in which the dressing is characterized by comprising: a collector comprising a first surface and a second surface opposite the first surface; a first layer adjacent to the first surface and a second layer adjacent to the second surface, wherein the first layer and the second layer each comprise a polymeric film; and a plurality of fluid restrictions on the polymeric film adjacent to at least the first surface.
[2]
2. DRESSING according to claim 1, characterized in that the polymeric film is hydrophobic.
[3]
3. DRESSING, according to claim 1, characterized by the polymeric film having a contact angle with water greater than 90 degrees.
[4]
4. DRESSING according to any one of claims 1 to 3, characterized in that the polymeric film is a polyethylene film.
[5]
5. DRESSING according to any one of claims 1 to 3, characterized in that the polymeric film is selected from the group consisting of polyethylene, polyurethane, acrylics, polyolefins, polyacetates, polyamides, polyesters, polyether block amide, thermoplastic vulcanized , polyethers and polyvinyl alcohol.
[6]
6. DRESSING according to any one of claims 1 to 3, characterized in that the polymeric film is a polyethylene film that has an area density of less than 30 grams per square meter.
[7]
7. DRESSING according to any one of claims 1 to 6, characterized in that fluid restrictions comprise a plurality of slits configured to allow fluid flow and inhibit the collector's exposure to the tissue site.
[8]
DRESSING according to any one of claims 1 to 6, characterized in that the fluid restrictions comprise a plurality of slits, each slit having a length of less than 4 millimeters.
[9]
DRESSING according to any one of claims 1 to 6, characterized in that the fluid restrictions comprise a plurality of slits, each slit having a width of less than 2 millimeters.
[10]
10. DRESSING according to any one of claims 1 to 6, characterized in that the fluid restrictions comprise a plurality of slits, each slit being less than 4 millimeters in length and less than 2 millimeters in width.
[11]
11. DRESSING, according to claim 10, characterized in that the width is less than 1 millimeter.
[12]
12. DRESSING according to claim 10, characterized in that the length is less than 3 millimeters and the width is less than 1 millimeter.
[13]
13. DRESSING according to claim 10, characterized in that the width is at least 0.5 millimeters.
[14]
14. DRESSING according to claim 10, characterized in that the length is at least 2 millimeters.
[15]
CURATIVE according to any one of claims 1 to 6, characterized in that the fluid restrictions comprise or consist essentially of elastomeric valves in the polymeric film which are normally closed.
[16]
16. DRESSING, according to claim 15, characterized in that the elastomeric valves are fenestrated.
[17]
17. DRESSING according to claim 15, characterized in that the elastomeric valves are grooved.
[18]
18. DRESSING according to claim 15, characterized in that the fluid restrictions comprise a plurality of grooves in the polymeric film, wherein each of the grooves is less than 4 millimeters long.
[19]
19. DRESSING, according to claim 18, characterized in that the length is less than 3 millimeters.
[20]
20. DRESSING according to claim 18 or 19, characterized in that the length is at least 2 millimeters.
[21]
21. DRESSING according to any one of claims 1 to 20, characterized in that the plurality of fluid restrictions in the polymeric film are adjacent to the first surface and the second surface.
[22]
22. DRESSING according to any one of claims 1 to 21, characterized in that the fluid restrictions are coextensive with the polymeric film.
[23]
23. DRESSING according to any one of claims 1 to 21, characterized in that fluid restrictions are coextensive with the collector.
[24]
24. DRESSING according to any one of claims 1 to 23, characterized in that the first layer and the second layer are laminated to the collector.
[25]
25. DRESSING according to any one of claims 1 to 23, characterized in that the first layer and the second layer form a sleeve around the collector.
[26]
26. DRESSING according to claim 25, characterized in that at least one edge of the collector is exposed through the sleeve.
[27]
27. DRESSING according to any one of claims 25 to 26, characterized in that the sleeve is configured to be interposed between the collector and the fabric location.
[28]
28. DRESSING according to any one of claims 25 to 27, characterized in that the sleeve comprises an exposed surface that is smooth.
[29]
29. DRESSING according to any one of claims 25 to 27, characterized in that the sleeve comprises an exposed surface that is matte.
[30]
30. DRESSING according to any one of claims 25 to 27, characterized in that the sleeve comprises an exposed surface that is not rough.
[31]
31. DRESSING according to any one of claims 1 to 30, characterized in that the collector comprises a foam.
[32]
32. DRESSING according to claim 31, characterized in that the foam is a polymeric foam.
[33]
33. DRESSING according to claim 31, characterized in that the foam is an ether-type polyurethane foam.
[34]
34. DRESSING according to claim 31, characterized in that the foam is open cell foam.
[35]
35. DRESSING according to claim 31, characterized in that the foam is cross-linked.
[36]
36. DRESSING according to claim 31, characterized in that the foam is a cross-linked polymeric foam.
[37]
37. DRESSING according to claim 31, characterized in that the foam is a cross-linked ether polyurethane foam.
[38]
38. DRESSING according to any one of claims 31 to 34, characterized in that the foam is cross-linked and has a free volume of at least 90%.
[39]
39. DRESSING according to any one of claims 31 to 38, characterized in that the foam is porous and has an average pore size in the range of 400 to 600 microns.
[40]
40. DRESSING according to any one of claims 1 to 39, characterized in that the collector has a thickness of less than 7 millimeters.
[41]
41. DRESSING according to any one of claims 1 to 39, characterized in that the collector has a thickness in the range of 2 millimeters to 7 millimeters.
[42]
42. DRESSING according to any one of claims 1 to 41, characterized in that the collector is hydrophobic.
[43]
43. DRESSING according to any one of claims 1 to 42, characterized in that fluid restrictions are distributed through the polymeric film in a uniform pattern.
[44]
44. DRESSING according to claim 43, characterized by the uniform pattern comprising a grid of parallel rows and columns.
[45]
45. DRESSING according to any one of claims 1 to 44, characterized by: fluid restrictions being distributed through the polymeric film in parallel rows and columns; where the rows are spaced about 3 millimeters in the center; and the fluid restrictions in each row are spaced about 3 millimeters in the center.
[46]
46. DRESSING according to claim 45, characterized in that fluid restrictions in adjacent rows are misaligned.
[47]
47. DRESSING according to any one of claims 1 to 46, characterized in that it further comprises: a surgical field arranged on the sleeve adjacent the second surface; and a fluid port coupled to the surgical field and fluidly coupled to the collector through the surgical field and the sleeve.
[48]
48. DRESSING according to any one of claims 1 to 47, characterized in that it further comprises a sealing layer adjacent to the sleeve, wherein the sealing layer has a plurality of openings fluidly coupled to the fluid restrictions.
[49]
49. DRESSING according to any one of claims 1 to 47, characterized in that it further comprises a sealing layer coupled to the sleeve, wherein the sealing layer comprises a hydrophobic gel that has a plurality of openings aligned with the fluid restrictions.
[50]
50. DRESSING according to any one of claims 1 to 47, characterized in that it further comprises a sealing layer coupled to the sleeve, wherein the fourth layer comprises a hydrophobic gel that has a plurality of openings in registration with at least some of the plurality of fluid restrictions.
[51]
51. DRESSING according to any one of claims 1 to 47, characterized in that it further comprises a sealing layer coupled to the sleeve, wherein the sealing layer comprises a hydrophobic gel that has a plurality of openings coextensive with the sealing layer and substantially all of the plurality of openings are on record with fluid restrictions.
[52]
52. DRESSING according to any one of claims 48 to 51, characterized in that the sealing layer comprises a silicone gel.
[53]
53. DRESSING according to any one of claims 48 to 51, characterized in that the sealing layer comprises a bonded silicone.
[54]
54. DRESSING according to any one of claims 1 to 47, characterized in that it further comprises a sealing layer coupled to the sleeve, wherein the sealing layer has a plurality of openings adjacent to the fluid restrictions and an area density less than 300 grams per square meter.
[55]
55. DRESSING according to any one of claims 48 to 54, characterized in that the sealing layer has a hardness of between about 5 Shore OO and about 80 Shore OO.
[56]
56. DRESSING according to any one of claims 48 to 55, characterized in that the sealing layer is configured to be interposed between the collector and the fabric location.
[57]
57. DRESSING according to any one of claims 48 to 56, characterized in that the fluid restrictions have an average size that does not substantially exceed an average size of the openings.
[58]
58. DRESSING according to any one of claims 48 to 57, characterized in that the openings limit an effective size of the fluid restrictions.
[59]
59. DRESSING according to any one of claims 48 to 58, characterized in that the surgical field and the sealing layer surround the sleeve and the collector.
[60]
60. DRESSING according to any one of claims 48 to 58, characterized in that the sealing layer has a smooth bottom surface.
[61]
61. DRESSING according to any one of claims 48 to 58, characterized in that the sealing layer is configured to provide an impermeable seal with the fabric location.
[62]
62. DRESSING according to any one of claims 48 to 61, characterized in that the surgical field and the sealing layer surround the collector and the sleeve, and the sealing layer is adapted to contact the tissue site.
[63]
63. DRESSING according to any one of claims 47 to 62, characterized in that the surgical field comprises a polymeric film.
[64]
64. DRESSING according to any one of claims 25 to 63, characterized in that the sleeve is joined to the collector.
[65]
65. DRESSING according to any one of claims 47 to 64, characterized in that the surgical field comprises a margin that extends beyond the collector and the sleeve, and an adhesive layer is arranged on the margin.
[66]
66. DRESSING according to any one of claims 1 to 65, characterized in that the dressing comprises a smooth surface configured to come into contact with the tissue site.
[67]
67. DRESSING according to any one of claims 1 to 65, characterized in that the dressing comprises a matte surface configured to come into contact with the tissue site.
[68]
68. DRESSING according to any one of claims 1 to 65, characterized in that the dressing comprises a surface that is not rough and is configured to come into contact with the tissue site.
[69]
69. DRESSING according to any one of claims 1 to 68, characterized in that the collector has a rough bottom surface and is not exposed to the tissue when the dressing is placed on the tissue site.
[70]
70. DRESSING, characterized by comprising: a collector formed from a hydrophobic material; a film that substantially involves the collector, in which the film is formed from a hydrophobic material; and a plurality of fluid passages through the film, wherein the plurality of fluid passages are configured to expand in response to a pressure gradient across the film.
[71]
71. DRESSING according to claim 70, further comprising: a polymer surgical field coupled to the film; a hydrophobic gel coupled to the film opposite the polymer surgical field, in which the hydrophobic gel has an area density of less than 300 grams per square meter; and a plurality of openings through the hydrophobic gel fluidly coupled to at least some of the plurality of fluid passages through the film.
[72]
72. DRESSING according to claim 70 or 71, characterized in that the film forms a sleeve around the collector.
[73]
73. Dressing according to claim 70 or 71, characterized in that the film forms an envelope around the collector.
[74]
74. CURATIVE, is characterized by comprising: a first layer comprising a first film that has a flat surface texture; a second layer adjacent to the first layer, the second layer comprising a collector; a third layer adjacent to the second layer opposite the first layer, the third layer comprising a second film having a flat surface texture; and a plurality of fluid constraints across the first film, wherein the plurality of fluid constraints is configured to be responsive to a pressure gradient across the fluid constraints.
[75]
75. DRESSING according to claim 74, characterized by the plurality of fluid restrictions being through the first film and the second film.
[76]
76. DRESSING according to either of Claims 74 or 75, characterized in that it further comprises: a fourth layer coupled to the third layer opposite the first layer, wherein the third layer comprises a polymer surgical field;
a fifth layer coupled to the first layer opposite the second layer, the fifth layer comprising a gel having an area density of less than 300 grams per square meter and a hardness between about 5 Shore OO and about 80 Shore OO; and a plurality of openings through the fifth layer aligned with at least some of the plurality of fluid constraints.
[77]
77. APPARATUS TO TREAT A FABRIC PLACE WITH NEGATIVE PRESSURE, in which the device is characterized by comprising: a fabric interface comprising a collector and a film covering at least two sides of the collector, where the collector and the film are formed from a hydrophobic material; a plurality of elastomeric valves across the film, wherein the plurality of elastomeric valves are configured to expand in response to a pressure gradient across the film; and a cover configured to be attached to the fabric location; wherein the cover and fabric interface are mounted in a stacked relationship with the cover configured to be attached to a fixation surface adjacent to the fabric location.
[78]
78. APPARATUS, according to claim 77, characterized in that the film is configured to be interposed between the collector and the fabric location.
[79]
79. Apparatus according to either of Claims 77 or 78, characterized in that the film comprises a polymeric film having an area density of less than 30 grams per square meter.
[80]
80. APPARATUS according to any one of claims 77 to 79, characterized in that the film comprises a polymeric film that has a contact angle with water greater than 90 degrees.
[81]
81. APPARATUS, according to any one of claims 77 to 80, characterized in that the film has a surface with variations in height that do not exceed 0.2 millimeters to 1 centimeter.
[82]
82. APPARATUS according to any one of claims 77 to 81, characterized in that the fabric interface further comprises a sealing layer adjacent to the film and configured to contact the fabric location, and at least one opening in the sealing layer fluidly coupled to at least one of the elastomeric valves in the film.
[83]
83. APPARATUS according to claim 82, characterized in that at least one of the openings is configured to expose at least a part of the film to the fabric location.
[84]
84. APPARATUS according to any one of claims 82 to 83, characterized in that at least one of the openings is configured to expose at least some of the elastomeric valves to the tissue site.
[85]
85. APPARATUS, according to claim 82, characterized in that at least some portion of the film is exposed through at least one of the openings.
[86]
86. APPARATUS, according to claim 82, characterized in that at least some portion of the elastomeric valves is exposed through the openings in the third layer.
[87]
87. DRESSING, characterized by comprising: a first layer comprising a film that has a flat surface texture; a second layer adjacent to the first layer, the second layer comprising a collector; and a plurality of fluid constraints across the film, wherein the plurality of fluid constraints are configured to be responsive to a pressure gradient across the fluid constraints.
[88]
88. SYSTEM FOR TREATING A TISSUE LOCATION, in which the system is characterized by comprising: the dressing or apparatus, as defined in any one of claims 1 to 87; and a source of negative pressure fluidly coupled to the dressing or apparatus.
[89]
89. SYSTEM, according to claim 88, characterized in that it further comprises a fluid container fluidly coupled between the dressing and the source of negative pressure.
[90]
90. USE OF ANY OF THE DRESSINGS OR APPLIANCES OR SYSTEMS, as defined in any one of claims 1 to 89, characterized by being for at least 5 days to promote granulation with a negative pressure source.
[91]
91. USE, as defined in any one of claims 1 to 89, characterized in that it is for at least 5 days to minimize tissue growth with a source of negative pressure.
[92]
92. METHOD FOR TREATING A SURFACE INJURY WITH NEGATIVE PRESSURE, wherein the method is characterized by comprising: applying the dressing or apparatus, as defined in any of claims 1 to 87, to a tissue site; seal the dressing or epidermis device adjacent to the tissue site; fluidly coupling the dressing or apparatus to a source of negative pressure; and applying negative pressure from the negative pressure source to the dressing or apparatus.
[93]
93. METHOD according to claim 92, characterized in that the collector is not substantially exposed to the tissue site during the step of applying negative pressure.
[94]
94. METHOD according to either of claims 92 or 93, characterized in that at least one of the first layer and the second layer is configured to be exposed to the tissue site during the negative pressure application step.
[95]
95. METHOD according to any one of claims 92 to 94, characterized in that the application of the dressing comprises arranging at least part of the dressing through an edge of the superficial wound.
[96]
96. METHOD according to any one of claims 92 to 95, characterized by the application of negative pressure to open fluid restrictions.
[97]
97. METHOD according to claim 96, characterized in that it further comprises reducing the negative pressure of the negative pressure source, in which the reduction of the negative pressure closes the fluid restrictions.
[98]
98. METHOD according to any one of claims 92 to 97, characterized in that it further comprises fluidly coupling a fluid container between the dressing and the negative pressure source, and transferring the extrudate from the dressing to the fluid container.
[99]
99. METHOD, according to any one of claims 92 to 98, characterized in that it further comprises applying a collector between the dressing and the superficial wound.
[100]
100. METHOD FOR PROMOTING GRANULATION IN A SURFACE WOUND, in which the method is characterized by comprising: applying a dressing to the superficial wound, in which the dressing comprises a collector that has a first surface and a second surface opposite the first surface, and a perforated polymeric film covering at least the first surface; and applying negative pressure from a negative pressure source to the dressing and promoting granulation; wherein the perforated polymer film is hydrophobic and is applied to the superficial wound.
[101]
101. METHOD, according to claim 100, characterized in that the perforated polymer film is polyethylene.
[102]
102. METHOD according to either of claims 100 or 101, characterized in that the perforated polymeric film has a smooth surface applied to the superficial wound.
[103]
103. METHOD according to any one of claims 100 to 102, characterized in that it further comprises: sealing the perforated polymer film to the superficial wound and covering at least a portion of a periphery adjacent to the superficial wound; fix the cover to the epidermis around the perforated polymeric film; and fluidly coupling the dressing to the negative pressure source.
[104]
104. METHOD, according to any of claims 100 to 103, characterized in that the dressing remains in the superficial wound for at least 5 days.
[105]
105. METHOD, according to any one of claims 100 to 103, characterized in that the dressing remains in the superficial wound for at least 7 days.
[106]
106. METHOD according to any one of claims 100 to 105, characterized in that the perforated polymeric film substantially prevents the exposure of tissue in the superficial wound to the collector and inhibits tissue growth in the collector.
[107]
107. METHOD according to any one of claims 100 to 106, characterized in that it further comprises applying a wound load between the perforated polymeric film and the superficial wound.
[108]
108. METHOD, according to claim 107, characterized in that the wound load is applied internally to the periphery.
[109]
109. METHOD according to claim 107 or 108, characterized in that the wound load is foam.
[110]
110. METHOD, according to any one of claims 100 to 109, characterized in that the dressing substantially prevents maceration of the periphery.
[111]
111. SYSTEMS, APPLIANCES AND METHODS, characterized by being substantially as described in this document.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112019025760A2|2020-06-23|DRESSING TO TREAT A FABRIC PLACE WITH NEGATIVE PRESSURE, APPLIANCE TO TREAT A FABRIC PLACE WITH NEGATIVE PRESSURE, SYSTEM TO TREAT A TISSUE PLACE, USE OF ANY OF THE DRESSINGS, APPLIANCES OR SYSTEMS, METHOD TO TREAT A SURFACE WOUND WITH PRESSURE PRESSURE , METHOD TO PROMOTE GRANULATION IN A SURFACE INJURY AND SYSTEMS, APPLIANCES AND METHODS

---

US20200008980A1|2020-01-09|Hybrid drape having a gel-coated perforated mesh

---

JP2020523082A|2020-08-06|Composite dressing to promote granulation and reduce maceration during negative pressure treatment

---

US20190192750A1|2019-06-27|Hybrid Sealing Tape

---

JP2020523073A|2020-08-06|Peel-off dressing for negative pressure treatment

---

US20190231600A1|2019-08-01|Systems, Apparatuses, And Methods For Negative-Pressure Treatment With Reduced Tissue In-Growth

---

KR20200016936A|2020-02-17|Customized composite dressing material for improving childcare and reducing smoke by using negative pressure treatment

---

JP2020523085A|2020-08-06|Peel-off dressing for thick exudates and drops

---

US20200085629A1|2020-03-19|Composite dressings with even expansion profiles for treatment of wounds using negative-pressure treatment

---

US20200000643A1|2020-01-02|Long-Duration, Deep Wound Filler With Means To Prevent Granulation In-Growth

---

US20180353338A1|2018-12-13|Customizable Composite Dressings For Improved Granulation And Reduced Maceration With Negative-Pressure Treatment

---

US20200246190A1|2020-08-06|Drape strip having selectable adhesive

---

JP2022518528A|2022-03-15|Removable and replaceable dressing interface for negative pressure therapy systems

同族专利:

---

公开号 | 公开日

---

CA3060591A1|2018-12-13|

---

CN110944688A|2020-03-31|

---

EP3634517A1|2020-04-15|

---

RU2019139911A|2021-07-09|

---

BR112019025020A2|2020-06-16|

---

US20180353334A1|2018-12-13|

---

US20180353341A1|2018-12-13|

---

SG11201911537WA|2020-01-30|

---

AU2018282188A1|2019-12-19|

---

JP2020523084A|2020-08-06|

---

US20180353336A1|2018-12-13|

---

CN110691572A|2020-01-14|

---

KR20200016928A|2020-02-17|

---

JP2020523072A|2020-08-06|

---

WO2018226616A1|2018-12-13|

---

SG11201909371PA|2019-11-28|

---

EP3634331A1|2020-04-15|

---

RU2019140648A|2021-07-12|

---

WO2018226705A1|2018-12-13|

---

CN110997029A|2020-04-10|

---

AU2018282148A1|2019-10-31|

---

KR20200016929A|2020-02-17|

---

CA3065381A1|2018-12-13|

---

JP2020523074A|2020-08-06|

---

WO2018226664A1|2018-12-13|

---

EP3634518A1|2020-04-15|

---

CA3066093A1|2018-12-13|

---

AU2018280128A1|2020-01-02|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

CA2071391C|1991-07-29|1998-05-05|Thomas H. Gilman|Vented wound dressing|

---

GB0011202D0|2000-05-09|2000-06-28|Kci Licensing Inc|Abdominal wound dressing|

---

GB0508531D0|2005-04-27|2005-06-01|Smith & Nephew|Sai with ultrasound|

---

GB0606661D0|2006-04-03|2006-05-10|Brightwake Ltd|Improvements relating to dressings|

---

GB2452720A|2007-09-11|2009-03-18|Ethicon Inc|Wound dressing with an antimicrobial absorbent layer and an apertured cover sheet|

---

EP2305328B1|2008-05-30|2017-11-01|KCI Licensing, Inc.|Reduced pressure, compression systems and apparatuses for use on joints|

---

GB0815078D0|2008-08-18|2008-09-24|Inotec Amd Ltd|Hyperbaric dressing and method|

---

US9421309B2|2009-06-02|2016-08-23|Kci Licensing, Inc.|Reduced-pressure treatment systems and methods employing hydrogel reservoir members|

---

US8469936B2|2009-07-15|2013-06-25|Kci Licensing, Inc.|Reduced-pressure dressings, systems, and methods employing desolidifying barrier layers|

---

US9061095B2|2010-04-27|2015-06-23|Smith & Nephew Plc|Wound dressing and method of use|

---

GB201008347D0|2010-05-19|2010-07-07|Smith & Nephew|Wound protection|

---

US8613733B2|2010-12-15|2013-12-24|Kci Licensing, Inc.|Foam dressing with integral porous film|

---

GB2488749A|2011-01-31|2012-09-12|Systagenix Wound Man Ip Co Bv|Laminated silicone coated wound dressing|

---

US9107990B2|2011-02-14|2015-08-18|Kci Licensing, Inc.|Reduced-pressure dressings, systems, and methods for use with linear wounds|

---

IN2015DN00399A|2012-07-16|2015-06-19|Univ Massachusetts|

---

MX369689B|2012-07-16|2019-11-19|Smith & Nephew Inc|Negative pressure wound closure device.|

---

EP3403624B1|2012-07-30|2020-09-02|KCI Licensing, Inc.|Reduced-pressure absorbent dressing, system for treating a tissue site, and method of manufacturing the dressing|

---

DE102013002521A1|2013-02-13|2014-08-14|Paul Hartmann Ag|Abdominal wound pad with lanyard|

---

EP3372209A1|2013-03-13|2018-09-12|Smith & Nephew, Inc.|Negative pressure wound closure device and systems and methods of use in treating wounds with negative pressure|

---

EP3744361A1|2013-10-30|2020-12-02|KCI Licensing, Inc.|Absorbent conduit and system|

---

WO2015168681A1|2014-05-02|2015-11-05|Kci Licensing, Inc.|Fluid storage devices, systems, and methods|

---

EP3797744A1|2014-05-09|2021-03-31|3M Innovative Properties Company|Dressing with contracting layer for linear tissue sites|

---

CA2952284A1|2014-06-18|2015-12-23|Smith & Nephew Plc|Wound dressing|

---

CN112121243A|2014-07-24|2020-12-25|凯希特许有限公司|Combined fluid instillation and negative pressure dressing|

---

EP3900685A4|2015-01-14|2021-10-27|3M Innovative Properties Co|Closed abdominal manifold dressing|

---

US20170095374A1|2015-10-05|2017-04-06|Daniel Stuart Lauer|Hemostatic bandage for mucosal membranes, kit containing the same, and method of using the same|GB201020236D0|2010-11-30|2011-01-12|Convatec Technologies Inc|A composition for detecting biofilms on viable tissues|

---

EP2648793B1|2010-12-08|2020-03-11|ConvaTec Technologies Inc.|Integrated system for assessing wound exudates|

---

ES2748519T3|2010-12-08|2020-03-17|Convatec Technologies Inc|Wound exudate system accessory|

---

WO2013066426A2|2011-06-24|2013-05-10|Kci Licensing, Inc.|Reduced-pressure dressings employing tissue-fixation elements|

---

GB2497406A|2011-11-29|2013-06-12|Webtec Converting Llc|Dressing with a perforated binder layer|

---

WO2018009873A1|2016-07-08|2018-01-11|Convatec Technologies Inc.|Fluid collection apparatus|

---

WO2019164618A1|2018-02-23|2019-08-29|Kci Licensing, Inc.|Dressing with bolster for linear tissue sites|

---

CA3123232A1|2018-12-13|2020-06-18|Clyra Medical Technologies, Inc.|Systems and methods for reducing contaminants in a portion of a patient|

---

CN113727686A|2019-04-24|2021-11-30|凯希特许有限公司|Hybrid adhesive tissue cover with applied stretch|

---

WO2021019460A1|2019-07-30|2021-02-04|Kci Licensing, Inc.|Negative-pressure dressing for foot treatment|

---

WO2021019461A1|2019-08-01|2021-02-04|Kci Licensing, Inc.|Dressing with epithelialization and scar reduction feature|

---

US11160917B2|2020-01-22|2021-11-02|J&M Shuler Medical Inc.|Negative pressure wound therapy barrier|

---

WO2021161215A1|2020-02-13|2021-08-19|Kci Licensing, Inc.|Wound dressing with dissolvable film|

---

WO2021165821A1|2020-02-17|2021-08-26|Kci Licensing, Inc.|Extremity dressings with improved ease of application|

法律状态:
2021-07-13| B25A| Requested transfer of rights approved|Owner name: 3M INNOVATIVE PROPERTIES COMPANY (US) |

---

2021-11-03| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

US201762516540P| true| 2017-06-07|2017-06-07|

---

US201762516550P| true| 2017-06-07|2017-06-07|

---

US201762516566P| true| 2017-06-07|2017-06-07|

---

US62/516,566|2017-06-07|

---

US62/516,550|2017-06-07|

---

US62/516,540|2017-06-07|

---

PCT/US2018/036074|WO2018226705A1|2017-06-07|2018-06-05|Composite dressings for improved granulation and reduced maceration with negative-pressure treatment|

---